Date: 2017-01-03
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Prima Biomed (Australia)
Product: IMP761
Action
mechanism: monoclonal inhibitor/immune checkpoint inhibitor. IMP761 is a humanised IgG4 monoclonal antibody that has been developed by staff in Prima’s laboratory in Châtenay-Malabry south of Paris. The product is believed to be the first agonist antibody of the immune checkpoint LAG-3. It is mechanistically distinct from any of the known LAG-3 antibodies.
Disease:
Therapeutic area: Autoimmune diseases
Country:
Trial details:
Latest
news: * On January 3, 2017, Prima BioMed announced that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761. This antibody, developed at the Company’s
laboratory in Châtenay-Malabry south of Paris, is believed to be the first agonist antibody of LAG-3.
Dr. Frédéric Triebel said “Even though IMP761 is an early stage product, we are very excited to have developed what we believe is the first ever agonist of LAG-3. Until now, therapeutic antibodies with agonistic properties have not been described for any of the three major immune checkpoints, CTLA-4, PD-1 or LAG-3. IMP761 promises the first opportunity for fine tuning of the immune response to an immune checkpoint target. This singular biological activity of IMP761 could benefit sufferers of certain autoimmune diseases by temporarily switching off activated LAG-3+ T cells that are damaging tissue or creating inflammatory responses.”
Prima CEO, Mr Marc Voigt commented “(...) IMP761 is early stage, in 2017 we will focus on pre-clinical development, including in vivo efficacy model studies, to better understand its potential applications.”
